Abstract:
Background: Type 2 diabetes mellitus (T2DM) is a chronic progressive
metabolic disorder and liraglutide is one of the glucagon-like peptide-1
(GLP-1) agonists that are used to decrease glucose levels in the blood and
help in weight loss in patients with T2DM. Bibliometric analysis is one of
the most common statistical methods used to evaluate the credibility,
quality, and impact of scholarly work.
Methods: We performed a systematic review and bibliometric
analysis over the last two decades (2000-2020) by search on the
WOS database for studies published in the literature on June 2021 by
using relevant keywords ("Diabetes Mellitus, Type II") AND
(Liraglutide). We extract the data of the most ten cited articles,
journals, countries, and years. The bibliometric analysis was
performed by HistCite software.
Results: There are 2500 records entered the bibliometric analysis and
divided into 1813 articles and 687 reviews. The highest-cited paper was
"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes". The LANCET
was the top-cited journal with a 7599 total global citation score (TGCS).
Novo Nordisk AS and USA were the most cited institution, countries in
order, and with a top number of publication records. Among the most cited
articles, 2016 was the first global citation year score (n=9585), while 2020
was the top in a number of publications records (n=310).
Conclusion: Our bibliometric analysis provides both quantitative and
qualitative analyses and gives insight on the citation frequency of top-cited
articles published in using liraglutide in the treatment of patients with
diabetes mellitus type 2.
